In a filing, PTC Therapeutics Inc revealed its CHIEF EXECUTIVE OFFICER Klein Matthew B. unloaded Company’s shares for reported $0.56 million on Aug 05 ’25. In the deal valued at $51.74 per share,10,739 shares were sold. As a result of this transaction, Klein Matthew B. now holds 337,767 shares worth roughly $14.63 million.
Then, Klein Matthew B. bought 10,739 shares, generating $555,663 in total proceeds.
Before that, Gravier Pierre sold 2,516 shares. PTC Therapeutics Inc shares valued at $124,441 were divested by the CHIEF FINANCIAL OFFICER at a price of $49.46 per share. As a result of the transaction, Gravier Pierre now holds 71,920 shares, worth roughly $3.11 million.
Truist initiated its PTC Therapeutics Inc [PTCT] rating to a Buy in a research note published on June 17, 2025; the price target was $80. A number of analysts have revised their coverage, including BofA Securities’s analysts, who increased its forecast for the stock in early May from “a Neutral” to “a Buy”. Citigroup also remained covering PTCT and has increased its forecast on May 07, 2025 with a “Neutral” recommendation from previously “Sell” rating. BofA Securities revised its rating on March 11, 2025. It rated PTCT as “a Neutral” which previously was an “an Underperform”.
Price Performance Review of PTCT
On Monday, PTC Therapeutics Inc [NASDAQ:PTCT] saw its stock fall -4.58% to $43.3. Over the last five days, the stock has lost -17.13%. PTC Therapeutics Inc shares have risen nearly 35.95% since the year began. Nevertheless, the stocks have fallen -4.08% over the past one year. While a 52-week high of $58.38 was reached on 03/17/25, a 52-week low of $29.01 was recorded on 05/06/25.
Levels Of Support And Resistance For PTCT Stock
The 24-hour chart illustrates a support level at 42.17, which if violated will result in even more drops to 41.05. On the upside, there is a resistance level at 45.43. A further resistance level may holdings at 47.56.
How much short interest is there in PTC Therapeutics Inc?
A steep rise in short interest was recorded in PTC Therapeutics Inc stocks on 2025-07-15, growing by 0.7 million shares to a total of 5.77 million shares. Yahoo Finance data shows the prior-month short interest on 2025-06-13 was 5.07 million shares. There was a rise of 12.13%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on March 07, 2025 when Scotiabank began covering the stock and recommended ‘”a Sector perform”‘ rating along with a $55 price target.
